Angel MatthewDirector · CEO and President · 10% owner
4
Filed Jun 23, 2026Period of report Mar 24, 20260001193125-26-279703
| Transaction | Security | Shares | Price | ValueValue (shares × price) | Held after | Ownership |
|---|---|---|---|---|---|---|
PurchaseMar 24, 2026 | Common StockF2F1F3 | 231,482 | $2.16 | $500.00K | 231,482 | IndirectBy Factor Bioscience Inc. |
Filing footnotes · 5
- F1On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.
- F2The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.
- F3The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.
- F4The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval.
- F5The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval.